卓正医疗今起招股：何小鹏及多家腾讯系AI企业参与基石

Group 1 - The core viewpoint of the article is that Zhuozheng Medical (2677.HK) is launching its IPO with a strong financial performance, contrasting with the industry's challenges [1] - The IPO will take place from January 29 to February 3, 2026, with a global offering of 4.75 million shares priced between HKD 57.7 and HKD 66.6 [1] - Zhuozheng Medical has achieved revenue growth from CNY 470 million in 2022 to CNY 690 million in 2023, and projected CNY 960 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [1] - The company's gross profit has increased significantly, from CNY 43.98 million in 2022 to CNY 130 million in 2023, and projected CNY 230 million in 2024, with a CAGR of 126.7% [1] - Zhuozheng Medical is expected to turn profitable in 2024, with adjusted net profits improving from a loss of CNY 1.23 billion in 2022 to a profit of CNY 10.7 million in 2024 [1] - The net cash flow from operating activities has shown steady growth, increasing from CNY 6.86 million in 2022 to CNY 12.4 million in 2023, and projected CNY 17.1 million in 2024 [1] Group 2 - Notable cornerstone investors in the IPO include leading third-party testing company Kingmed Diagnostics and He Xiaopeng, founder of Xpeng Motors, enhancing Zhuozheng Medical's IPO [2] - Several Tencent-affiliated listed companies are participating in the cornerstone investment, including Minglue Technology, Weimeng Group, Kuro Game, and Shouhui Group [2]